Application of wedelolide in the preparation of anti-pulmonary fibrosis drugs

A technology of wedelolide and pulmonary fibrosis, applied in the field of chemical substances, can solve the problems of ineffective effect of pulmonary fibrosis, can not finally slow down or terminate lung tissue, etc., and achieve the effect of wide practical value, low cost and clear pharmacological activity
CN103816148BActive Publication Date: 2016-08-17CHINA PHARM UNIV
6 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
CHINA PHARM UNIV
Publication Date
2016-08-17

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention relates to a drug application of a chemical substance wedelolactone for treatment of pulmonary fibrosis. The chemical substance wedelolactone is derived from a traditional Chinese medicine eclipta, and the structure is determined through spectral data; the wedelolactone can significantly improve the degree of model mouse lung tissue pulmonary fibrosis after intragastric administration, reduce NO (Nitrogen Oxide) and MDA (Methylene dioxyamphetamine) contents reflecting degree of lung injury, HYP (Hydroxyproline) content reflecting collagen deposition in the lung tissues, and cell factor TGF-beta 1 (Transforming Growth Factor) content causing pulmonary fibrosis, and inhibit human embryo lung fibroblast proliferation in vitro and HYP content of the human embryo lung fibroblast. In-vivo and in-vitro experiments show that wedelolactone can obviously improve bleomycin induced mouse pulmonary fibrosis, so that the wedelolactone can be taken as a novel drug for treating pulmonary fibrosis.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention relates to a new application of chemical substance wedelolide as a drug for treating pulmonary fibrosis. Background technique

[0002] Pulmonary fibrosis is a progressive disease characterized by fibrosis and lung parenchymal remodeling. Pulmonary fibroblasts hyperproliferate, transdifferentiate into myofibroblasts, secrete a large amount of collagen and deposit matrix. There is no effective treatment. Bleomycin-induced pulmonary fibrosis animal model is the most commonly used. Pulmonary fibrosis induced by tracheal administration of bleomycin is a classic animal model for studying pulmonary fibrosis drugs at home and abroad. Bleomycin can cause inflammation and fibrosis of lung tissue in a short period of time, and increase pro-fibrotic markers such as TGF -Expression of β1, α-SMA, etc. Generally speaking, the bleomycin animal model begins to show fibrosis symptoms 9 days after modeling, and typical fibrosis symptoms appear on 21 days ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More